Gene Panel Market Report Scope & Overview:

The Gene Panel Market Size is valued at USD 3.68 Billion in 2025 and is projected to reach USD 17.18 Billion by 2035, growing at a CAGR of 16.69% during the forecast period 2026–2035.

The Gene Panel Market analysis report provides a comprehensive overview of growth opportunities in genomic testing and precision medicine. Demand for early diagnosis of diseases, expanding uses in cancer and genetic disorders, and advancements in next-generation sequencing technologies are major factors that will propel market growth from 2026 to 2035.

Gene panel testing exceeded 10 million tests in 2025, driven by rising adoption in oncology, genetic disease screening, and precision medicine applications.

Market Size and Forecast:

• Market Size in 2025: USD 3.68 Billion

• Market Size by 2035: USD 17.18 Billion

• CAGR: 16.69% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get More Information On Gene Panel Market - Request Free Sample Report

Gene Panel Market Trends:

• Rising adoption of precision medicine and oncology diagnostics is accelerating demand for multi-gene panel testing in clinical decision-making.

• Increasing use of next-generation sequencing (NGS) platforms is improving accuracy, scalability, and turnaround time of gene panel assays.

• Growing prevalence of cancer and genetic disorders is driving the need for early detection and comprehensive genetic screening solutions.

• Expansion of pharmacogenomics is enabling personalized drug selection and dosage optimization based on genetic profiles.

• Shift toward customized and disease-specific gene panels is enhancing targeted diagnostics and research applications.

• Increasing integration of bioinformatics and AI-driven data analysis is improving interpretation of complex genomic data.

• Rising adoption in hospitals, diagnostic labs, and research institutes is expanding the commercial and clinical footprint of gene panel testing.

U.S. Gene Panel Market Insights:

The U.S. Gene Panel Market is projected to grow from USD 1.32 Billion in 2025 to USD 5.94 Billion by 2035, at a CAGR of 16.22%. According to the features of adoption precision medicine, cancer and genetic disorder occurrences, foundations for healthcare delivery systems, the greater utilization of NGS technologies drives growth in demand for early diagnosis and personalized treatment solutions.

Gene Panel Market Growth Drivers:

• Increasing demand for precision oncology and early genetic disease detection is accelerating gene panel market growth.

One of the major factors that is contributing to the expansion of the Gene Panel Market is the increased demand for precision oncology and early genetic disease detection. As healthcare providers increasingly adopt the personalized medicine approach, gene panels offer the opportunity to analyze the full spectrum of genes in a single test. This is further enhancing the accuracy of diagnostic tests and the decision-making process with the identification of genetic mutations associated with various cancers and inherited diseases.

Over 55% of oncology diagnostic tests in 2025 incorporated gene panel or NGS-based assays, driven by increasing demand for precision medicine and early genetic mutation detection.

Gene Panel Market Restraints:

• High cost of gene panel testing and limited reimbursement coverage restricting widespread clinical adoption.

The high cost of gene panel testing and the limited reimbursement coverage are the major restraints for the Gene Panel Market. High sequencing costs are associated with the development of cutting-edge sequencing equipment and the requirement for skilled labor. In some parts of the world, insurance coverage for genetic testing is still in the early stages of development. This is a major restraint for the Gene Panel Market due to the increased cost burden on patients.

Gene Panel Market Opportunities:

• Growing adoption of liquid biopsy and non-invasive testing technologies creating new opportunities for gene panel applications.

The rise in acceptance of liquid biopsy and non-invasive technologies is a significant opportunity for the Gene Panel Market. These technologies allow gene panels to analyze circulating tumor DNA and other biomarkers in blood samples, reducing the requirement for invasive biopsies. This is more comfortable for patients, allows for early detection of diseases, and facilitates real-time monitoring of patient response to treatments. Clinical acceptance, combined with advancements in sequencing technologies, is leading to gene panel acceptance in clinical settings.

Over 42% of new oncology diagnostic workflows in 2025 incorporated liquid biopsy-based gene panel testing, supporting non-invasive precision medicine adoption.

Gene Panel Market Segmentation Analysis:

• By Application, Oncology (Cancer) held the largest share of 47.56% in 2025, whereas Pharmacogenomics is expected to grow at the fastest CAGR of 19.28% through 2026–2035.

• By Product & Service, Test Kits held the largest market share of 58.34% in 2025, while Testing Services are expected to grow at the fastest CAGR of 17.92% during 2026–2035.

• By Technology / Technique, Hybridization-Based Sequencing accounted for the highest market share of 54.21% in 2025, whereas Amplicon-Based Sequencing is projected to register the fastest CAGR of 18.45% through 2026–2035.

• By Design, Predesigned Gene Panels dominated with a 61.78% market share in 2025, while Customized Gene Panels are anticipated to expand at the fastest CAGR of 17.36% during the forecast period.

• By End User, Hospitals & Diagnostic Laboratories captured the highest market share of 52.89% in 2025, while Pharmaceutical & Biotechnology Companies are projected to grow at the fastest CAGR of 18.67% during the forecast period.

By Application, Oncology (Cancer) Dominated While Pharmacogenomics Is Fastest Growing:

Oncology segment dominated the market owing to the increasing burden of cancer and the crucial part of gene panels in detecting any mutations for effective targeted therapies. Over 4 million oncology-associated gene panel tests were conducted in clinical laboratories in 2025, illustrating their integral role in tumor profiling and treatment selection.

Pharmacogenomics is the fastest-growing segment with personalized drug therapies based on genetic makeup being rapidly adopted by health care systems. An increasing focus on maximizing drug effectiveness, reducing side effects, and improving therapeutic outcomes is fuelling the growth of pharmacogenomic testing in clinic.

By Product & Service, Test Kits Dominated While Testing Services Are Fastest Growing:

Test Kits segment dominated the market due to their extensive use in clinical diagnostics, standardized workflows and compatibility with high-throughput sequencing systems. In 2025 alone, more than 10 million gene panel tests were performed using kit-based solutions that continued to dominate the market.

Testing Services are the fastest-growing segment as outsourcing genomic analysis to specialized providers minimizes infrastructure cost. Growing demand for third-party testing services is driven by the adoption of smaller labs and research institutions.

By Technology / Technique, Hybridization-Based Sequencing Dominated While Amplicon-Based Sequencing Is Fastest Growing:

Hybridization-Based Sequencing segment dominated the market as it is capable of capturing a variety of genomic regions with high specificity and accuracy which is ideal for comprehensive cancer & rare disease panels. In 2025, the predominant method for large-scale gene panels in both clinical and research, with over 60% of workflows relying heavily on this approach.

Amplicon-Based Sequencing is the fastest-growing segment due to its lower cost; quicker turnaround time compared to whole-genome sequencing and its propriety for target panels. Amplicon-based approaches are being adopted rapidly, particularly with increasing use in smaller diagnostic labs and rapid testing applications.

By Design, Predesigned Gene Panels Dominated While Customized Gene Panels Are Fastest Growing:

Predesigned Gene Panels segment dominated the market with its standardized sets of genes for common diseases, thus reducing development time and ensuring regulatory approval. More than two-thirds of routine diagnostics workflows utilized predesigned panels due to ease of implementation.

Customized Gene Panels are the fastest-growing segment, due to booming demand in personalized medicine and certain studies. The usage of specialized gene panel solutions across the progressive clinical and analysis settings is being propelled with a rising emphasis on patient-specific mutations, and rare disease profiling.

By End User, Hospitals & Diagnostic Laboratories Dominated While Pharmaceutical & Biotechnology Companies Are Fastest Growing:

Hospitals and diagnostic laboratories segment dominated the markets they serve as centers for patient testing, disease diagnosis, and clinical decision-making. The volume of testing for gene panels was over 50% from these facilities, which is explained by the increasing integration of genomic diagnostics into everyday healthcare.

Pharmaceutical and biotechnology companies are the fastest-growing segment, with pharmaceutical and biotech companies being the fastest-growing segment. Growing investment in precision medicine research and companion diagnostics development are speeding adoption among life sciences companies, broadening their role within the gene panel ecosystem.

Gene Panel Market Regional Analysis:

North America Gene Panel Market Insights:

North America dominates the Gene Panel Market, accounting for a market share of 41.62% in 2025. Factors such as the adoption of precision medicine, rising healthcare spending levels and the development of next-generation sequencing technologies are propelling growth for this market in this region. Increasing prevalence of cancer and genetic diseases is driving the market for gene panel tests in clinical diagnostics. In the United States and Canada, high expenditure on healthcare and beneficial reimbursement policies in the region in addition to presence of key biotech and genomics providers reinforce the market.

Get Customized Report as Per Your Business Requirement - Enquiry Now

U.S. Gene Panel Market Insights:

The U.S. Gene Panel Market is due to robust adoption rates of precision oncology, advanced healthcare infrastructure, and high genomic research spending. Presence of major biotech players, widespread adoption of NGS in diagnostics, and increasing adoption in pharmacogenomics and clinical decision support also add strength to market growth and reiterates the country’s position at the forefront.

Asia-Pacific Gene Panel Market Insights:

The Asia-Pacific Gene Panel Market is the fastest-growing regional segment, expected to expand at a CAGR of 18.78% during 2026–2035, fuelled by the growing adoption of precision medicine and advancements in genomics research infrastructure. Cancer prevalence rates, awareness of genetic testing services, and improvements in healthcare infrastructure in nations such as China, India, and Japan are some of the factors that are propelling this regional market. Availability of cost-effective testing services and improvements in clinical laboratory infrastructure are also accelerating this regional market.

China Gene Panel Market Insights:

The China Gene Panel Market is driven by the increasing demand for precision medicine, the prevalence of cancer cases, and the rising adoption of genomic tests in clinical diagnostics. Strong support for biotechnology development from the government, increasing investments in healthcare infrastructure, and the development of next-generation sequencing technologies are the factors that make China an important contributor in the Asia-Pacific region.

Europe Gene Panel Market Insights:

Europe is a steadily growing region in the Gene Panel Market, due to the increasing application of precision medicine and genetic testing in clinical diagnostics. Market growth is favoured by the increased prevalence of cancer and hereditary diseases along with a strong healthcare infrastructure. The growing research activities, favorable regulations along with the adoption of next-generation sequencing technologies are also fueling market adoption. But steady market growth in this region is also being accelerated by research collaborations, established biotech industries and an increasing appreciation of personalized healthcare.

Germany Gene Panel Market Insights:

Germany serves as a crucial player in the Europe Gene Panel Market, driven by advancements in healthcare infrastructure and increased acceptance of precision diagnostics. This is due to increasing demand for early disease detection, rising number of cancer cases, growing adoption of next-generation sequencing and increasing integration of genomic testing in hospitals and research institutions.

Latin America Gene Panel Market Insights:

The Latin America Gene Panel Market is growing owing to the increased adoption of genetic tests and awareness of precision medicine. Countries such as Brazil, Mexico, and Argentina are enhancing their healthcare infrastructure. An increased incidence of cancer cases, advances in diagnostic tools, improved access to sequencing tools, and investments in biotechnology are some of the factors driving the regional market.

Middle East and Africa Gene Panel Market Insights:

The Middle East & Africa Gene Panel Market is driven by the increasing awareness of genetic testing and precision medicine. Countries such as the UAE, Saudi Arabia, and South Africa are building healthcare infrastructure and diagnostic facilities. Increasing prevalence of cancer cases, expansion of laboratory infrastructure, increased access to sequencing technologies, and the adoption of personalized healthcare are driving the regional market.

Gene Panel Market Competitive Landscape:

Illumina, Inc. is a genomics and next-generation sequencing (NGS) technology company prominent in gene panel testing. With Lesion discovered, Illumina can take pride as having strongholds in this lucrative and the fastest pace evolving market of genetic testing industry with advanced evolutionary sequencing platforms, assured accuracy & scalable solutions for research & clinical diagnostic needs. Its powerful ecosystem of instruments, consumables and bioinformatics tools also allows for the end-to-end genomics workflows. The present work is based on Illumina's innovation, its adoption in oncology, and genetic basis massive collaborations reach making it a leader with Gene Panel Market.

• In February 2026, Illumina launched TruPath™ Genome, a comprehensive genome sequencing solution with simplified workflow and enhanced detection of rare genetic variants, reinforcing its leadership in genomic insight and precision diagnostics.

Thermo Fisher Scientific is a major factor in the Gene Panel Market with its sequencing platforms, reagents and genomic analysis solutions. With Ion Torrent sequencing technology and integrated lab solutions, the company accommodation gene panel workflows. Its dominance is due to robust distribution channels, a diverse product portfolio and extensive presence in both clinical diagnostics and life sciences research. Moreover, Thermo Fisher's focus on offering integrated solutions partnering with healthcare providers and advancements in precision medicine edge it further ahead in gaining competitive advantage.

• In December 2025, Thermo Fisher Scientific introduced the Applied Biosystems SwiftArrayStudio Microarray Analyzer, a scalable genotyping platform that accelerates genomic analysis and supports pharmacogenomics and broader genetic research workflows.

Agilent Technologies is a key player in the Gene Panel Market, provides hybridization-based target enrichment solutions, probes and sequencing-related tools. The SureSelect gene panel platforms are enriched for high-throughput oncology research and clinical diagnostics RNA sequencing. The superiority of the system is derived from wide assay performance, and reliability with massive adoption in research labs and diagnostic centers. The Company's focus on innovation, partnerships with genomic researchers, and market-relevant product development have only solidified Agilent's reputation as a trusted provider of gene panel solutions.

• In April 2025, Agilent showcased optimized Avida cancer gene panels with streamlined workflows for rapid detection of cancer-related genomic alterations from liquid biopsy samples, enhancing its targeted sequencing offerings.

Gene Panel Market Key Players:

Some of the Gene Panel Market Companies are: 

• Illumina, Inc.

• Thermo Fisher Scientific

• Agilent Technologies

• QIAGEN N.V.

• Roche / Roche Diagnostics

• BGI Genomics

• Eurofins Genomics

• Invitae Corporation

• Myriad Genetics / Myriad Genetic Laboratories

• Bio-Rad Laboratories

• Personalis, Inc.

• Genewiz (Azenta)

• Twist Bioscience

• ArcherDX (Invitae)

• Centogene NV

• Integrated DNA Technologies (IDT)

• PerkinElmer

• Becton, Dickinson and Company (BD)

• Guardant Health

• Sophia Genetics